Fluorouracil

Generic Name
Fluorouracil
Brand Names
Actikerall, Carac, Efudex, Fluoroplex, Tolak
Drug Type
Small Molecule
Chemical Formula
C4H3FN2O2
CAS Number
51-21-8
Unique Ingredient Identifier
U3P01618RT
Background

A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication

For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions
Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
Associated Therapies
-
Clinical Trials
Related News

An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

First Posted Date
2018-01-30
Last Posted Date
2023-11-18
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
196
Registration Number
NCT03414983
Locations
🇺🇸

Local Institution - 0033, Arlington Heights, Illinois, United States

🇺🇸

Local Institution - 0005, Philadelphia, Pennsylvania, United States

🇺🇸

Uab Comprehensive Cancer Center, Birmingham, Alabama, United States

and more 46 locations

CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

First Posted Date
2018-01-02
Last Posted Date
2021-02-26
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
112
Registration Number
NCT03387592
Locations
🇮🇹

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy

🇮🇹

Azienda Ospedaliera-Universitaria di Modena, Modena, MO, Italy

🇮🇹

Ospedale Civile degli Infermi, Faenza, RA, Italy

and more 20 locations

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

First Posted Date
2017-12-29
Last Posted Date
2024-08-05
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
4
Registration Number
NCT03387111
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

First Posted Date
2017-12-29
Last Posted Date
2024-08-09
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
9
Registration Number
NCT03387085
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

First Posted Date
2017-12-29
Last Posted Date
2019-04-18
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT03386838
Locations
🇺🇸

Allegheny General Hospital, Pittsburgh, Pennsylvania, United States

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

First Posted Date
2017-12-29
Last Posted Date
2024-05-22
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
4
Registration Number
NCT03387098
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

Intralesional 5-Fluorouracil (5FU), Topical Imiquimod Treatment for SCC

First Posted Date
2017-12-12
Last Posted Date
2024-10-04
Lead Sponsor
Melissa Pugliano-Mauro
Target Recruit Count
30
Registration Number
NCT03370406
Locations
🇺🇸

St. Margaret Hospital Dermatology, Pittsburgh, Pennsylvania, United States

mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

First Posted Date
2017-12-07
Last Posted Date
2023-02-14
Lead Sponsor
Huashan Hospital
Target Recruit Count
63
Registration Number
NCT03365765
Locations
🇨🇳

Huashan Hospital Affiliated to Fudan University, Shanghai, China

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

First Posted Date
2017-11-30
Last Posted Date
2024-06-28
Lead Sponsor
Incyte Corporation
Target Recruit Count
89
Registration Number
NCT03358472
Locations
🇺🇸

U of Kansas Cancer Center, Westwood, Kansas, United States

🇦🇺

Royal Brisbane & Women s Hospital, Herston, Queensland, Australia

🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

and more 70 locations

Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy

First Posted Date
2017-11-21
Last Posted Date
2017-11-21
Lead Sponsor
Zhiyong Yu
Target Recruit Count
200
Registration Number
NCT03349177
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy